| Literature DB >> 25597274 |
Yuqing Wang1, Chuangli Hao1, Wei Ji1, Yongdong Yan1, Xuejun Shao2, Jun Xu2.
Abstract
Viruses cause most cases of bronchiolitis in infants; consequently the importance of other agents such as Mycoplasma pneumoniae (MP) in the etiology of bronchiolitis may not be fully recognized. We investigated the prevalence and seasonal distribution of bronchiolitis caused by MP in 674 children admitted to the Children's Hospital affiliated with Soochow University from January 2010 to December 2012. The presence of MP was confirmed by real-time PCR. During the 3 years, we identified MP in 17.2% of the children with bronchiolitis. The annual MP detection rates were 16.6% in 2010, 17.8% in 2011, and 17.2% in 2012. MP was detected throughout the year, with a peak from July to September. The median age of MP-positive children was 10 months. Common clinical manifestations included cough, wheezing, and high fever. Moist and/or wheezing rales were frequent, and pulmonary interstitial infiltration was seen in 66.4% of chest X-rays. Patients with MP infection were older, were more likely to have pulmonary interstitial infiltration, and had shorter hospital stays than those with respiratory syncytial virus infection. Our study revealed MP as an important cause of bronchiolitis, with peaks of occurrence during the summer and early autumn. Pulmonary interstitial infiltrations were a common event.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25597274 PMCID: PMC4297954 DOI: 10.1038/srep07846
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The prevalence and seasonal distribution of MP bronchiolitis in children in the Suzhou region between January 2010 and December 2012.
Overall characteristics of patients with MP bronchiolitis
| Characteristics | No. of patients (%) |
|---|---|
| Age | |
| <6 months | 22 (8.9) |
| 6 months–1 year | 56 (23.9) |
| 1–2 years | 36 (18.6) |
| Sex | |
| Male | 60 (51.7) |
| Female | 56 (48.3) |
| Fever (°C) | |
| <38 | 1 (5.6%) |
| 38–39 | 5 (13.1%) |
| >39 | 32 (37.2%) |
| Symptom | |
| Cough | 116 (100) |
| Wheezing | 116 (100) |
| Tachypnea | 13 (11.2) |
| Dyspnea | 13 (11.2) |
| Vomiting/diarrhea | 33 (28.4) |
| Physical examination | |
| Lung wheezing rales | 89 (76.7) |
| Lung crackles | 9 (7.8) |
| SaO2 < 90% | 7 (6) |
| Lab test | |
| WBC (×109/l) | 7.7 ± 3.5 |
| CRP (mg/L) | 8.5 ± 3.8 |
| Blood platelet counts > 400 × 109/l | 79 (68.1) |
| ALT↑ | 30 (25.8) |
| CK-MB↑ | 41 (35.5) |
| Abnormal chest X-ray | |
| Interstitial infiltration | 77 (66.4) |
| Patchy shadows | 14 (12.1) |
| Emphysema | 19 (16.4) |
Data are expressed as number of patients (%) unless otherwise indicated.
WBC, white blood cell counts; CRP, C-reactive protein; ALT, alanine transaminase; CK-MB, creatine kinase-MB.
Figure 2Radiographic characteristics of a patient with Mycoplasma bronchiolitis.
Thickened lung markings accompanied by fuzzy, messy, reticular high-density shadows, with prominence in the hilar region are seen on this chest X-ray.
Figure 3Radiographic characteristics of a patient infected with respiratory syncytial virus.
The chest X-ray shows increased brightness in both right and left lungs.
Characteristics of patients with bronchiolitis caused by MP or RSV
| Characteristic | MP (n = 116), n (%) | RSV (n = 343), n (%) | χ2/Z test | |
|---|---|---|---|---|
| Mean age [months (range)] | 10.0 (6.0–15.0) | 5.2 (3.0–9.0) | 8.11 | <0.001 |
| <6 months | 22 (19) | 208 (60.6) | 60.224 | <.0001 |
| 6 months–1 year | 56 (48.3) | 84 (24.5) | 23.1362 | <.0001 |
| 1–2 years | 38 (32.7) | 51 (14.9) | 17.7494 | <.0001 |
| Sex | ||||
| Male | 60 (51.7) | 257 (74.9 | 21.84 | <0.001 |
| Female | 56 (48.3) | 86 (25.1) | 21.8426 | <0.0001 |
| Fever (°C) | 38 (32.8) | 92 (26.8) | 1.51 | >0.05 |
| <38 | 1 (5.6) | 80 (23.3) | 30.09 | <0.001 |
| 38–39 | 5 (13.1) | 11 (3.2) | 0.07 | >0.05 |
| >39 | 32 (27.6) | 1 (0.3) | 96.78 | <0.001 |
| Symptom | ||||
| Cough | 116 (100) | 340 (99.1) | Fisher's | 0.5751 |
| Wheezing | 116 (100) | 343 (100) | Fisher's | 1 |
| Tachypnea | 13 (11.2) | 98 (28.6) | 14.2557 | 0.0002 |
| Dyspnea | 13 (11.2) | 86 (25.1) | 9.8521 | 0.0017 |
| Vomiting/diarrhea | 33 (28.4) | 67 (19.8) | 4.0429 | 0.0444 |
| Physical examination | ||||
| Lung wheezing rales | 89 (76.7) | 270 (79.6) | 0.2021 | 0.6531 |
| Lung crackles | 9 (7.8) | 32 (9.3) | 0.2629 | 0.6081 |
| SaO2 < 90% | 7 (6.0) | 89 (25.9) | 20.78 | <0.001 |
| Lab tests | ||||
| WBC (×109/L) ± | 7.7 ± 3.5 | 7.2 ± 2.9 | 9.84 | >0.05 |
| CRP (mg/L) ± | 8.5 ± 3.8 | 7.6 ± 2.3 | 10.02 | >0.05 |
| Platelet count > 400 × 109/l | 79 (68.1) | 109 (31.7) | 15.3 | <0.05 |
| ALT↑ | 30 (25.8) | 31 (9) | 21.29 | <0.001 |
| CK-MB↑ | 41 (35.5) | 33 (9.6) | 42.42 | <0.001 |
| Chest X-ray | ||||
| Patchy shadow | 14 (12.1) | 68 (19.8) | 3.55 | >0.05 |
| Pulmonary emphysema | 19 (16.4) | 231 (67.3) | 90.79 | <0.001 |
| Pulmonary interstitial infiltration | 77 (66.4) | 44 (12.8) | 128.06 | <0.001 |
| Mean hospital stay [days (range)] | 7.0 (6.3–9.0) | 8.0 (7.0–9.0) | 5.73 | <0.001 |
| Medical history | ||||
| Premature birth | 18 (15.5) | 40 (11.7) | 1.17 | >0.05 |
| Breast feeding | 76 (65.5) | 198 (57.7) | 2.19 | >0.05 |
| Eczema | 38 (32.8) | 105 (30.6) | 0.19 | >0.05 |
| Family history of asthma | 14 (12.1) | 34 (9.9) | 0.43 | >0.05 |
Data are expressed as number of patients (%) unless otherwise indicated.
MP, Mycoplasma pneumonia; RSV, respiratory syncytial virus; WBC, white blood cell counts; CRP, C-reactive protein; ALT, alanine transaminase; CK-MB, creatine kinase-MB.
Amplification of MP, hMPV and hBoV genes
| Gene | Sequence | Size (bp) | |
|---|---|---|---|
| MP | Forward | 5′-CCA ACCAAA CAA CAA CGT TCA-3′ | 76 |
| Reverse | 5′-ACC TTG ACTGGA GGC CGT TA-3′ | ||
| Probe | 5′-FAM-TCA ACT CGA ATA 'ACG GTG ACTTCT TAC CAC TG-3′-TAMRA | ||
| hMPV | Forward | 5′-AACCGTGTACTAAGTGATGCACTC-3′ | 213 |
| Reverse | 5′-CATTGTTTGACCGGCCCCATAA-3′ | ||
| hBoV | Forward | 5′-TGACATTCAACTACCAACAACCTG-3′ | 92 |
| Reverse | 5′-CAGATCCTTTTCCTCCTCCAATAC-3′ | ||
| Probe | 5′-FAM-AGCACCACAAAACACCTCAGGGG-3′-TAMRA |
MP, Mycoplasma pneumonia; hMPV, human metapneumovirus; hBoV, human bocavirus; FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine.